A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer(TORG1632).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2018
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 16 May 2017 New trial record